News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
192,927 Results
Type
Article (7998)
Company Profile (11)
Press Release (184918)
Section
Business (75829)
Career Advice (449)
Deals (10968)
Drug Delivery (15)
Drug Development (21966)
Employer Resources (52)
FDA (4150)
Job Trends (4047)
News (112250)
Policy (8128)
Tag
2024 BioMidwest Digital (1)
2024 Biotech Bay Standard (2)
2025 Lone Star Bio Digital (1)
Academia (679)
Adcomms (11)
Allergies (24)
Alliances (13027)
ALS (13)
Alzheimer's disease (401)
Antibody-drug conjugate (ADC) (25)
Approvals (4190)
Artificial intelligence (62)
Autoimmune disease (1)
Automation (2)
Bankruptcy (72)
Best Places to Work (3427)
BIOSECURE Act (3)
Biosimilars (16)
Biotechnology (7)
Bladder cancer (13)
Brain cancer (6)
Breast cancer (49)
Cancer (551)
Cardiovascular disease (30)
Career advice (377)
Career pathing (10)
CAR-T (25)
Cell therapy (86)
Cervical cancer (7)
Clinical research (18403)
Collaboration (211)
Compensation (24)
Complete response letters (2)
COVID-19 (504)
CRISPR (11)
C-suite (72)
Cystic fibrosis (18)
Data (555)
Decentralized trials (1)
Denatured (3)
Depression (4)
Diabetes (72)
Diagnostics (1978)
Digital health (5)
Diversity (1)
Diversity, equity & inclusion (15)
Drug discovery (29)
Drug pricing (10)
Drug shortages (2)
Duchenne muscular dystrophy (12)
Earnings (42387)
Editorial (2)
Employer branding (8)
Employer resources (47)
Events (27010)
Executive appointments (186)
FDA (4413)
Featured Employer (4)
Frontotemporal dementia (3)
Funding (122)
Gene editing (23)
Generative AI (7)
Gene therapy (59)
GLP-1 (114)
Government (951)
Grass and pollen (1)
Guidances (22)
Healthcare (5015)
Huntington's disease (1)
IgA nephropathy (1)
Immunology and inflammation (12)
Indications (11)
Infectious disease (537)
Inflammatory bowel disease (31)
Influenza (12)
Intellectual property (22)
Interviews (66)
IPO (5591)
IRA (2)
Job creations (799)
Job search strategy (348)
Kidney cancer (7)
Labor market (2)
Layoffs (72)
Leadership (3)
Legal (1493)
Liver cancer (20)
Lung cancer (102)
Lymphoma (39)
Machine learning (1)
Management (19)
Manufacturing (59)
MASH (2)
Medical device (4153)
Medtech (4153)
Mergers & acquisitions (5464)
Metabolic disorders (124)
Multiple sclerosis (18)
Neurodegenerative disease (14)
Neuropsychiatric disorders (2)
Neuroscience (501)
NextGen: Class of 2025 (1583)
Non-profit (1201)
Northern California (532)
Now hiring (2)
Obesity (61)
Opinion (38)
Ovarian cancer (24)
Pain (11)
Pancreatic cancer (17)
Parkinson's disease (44)
Patents (35)
Patient recruitment (24)
Peanut (17)
People (18636)
Pharmaceutical (8)
Phase I (4879)
Phase II (7759)
Phase III (6991)
Pipeline (392)
Podcasts (6)
Policy (9)
Postmarket research (793)
Preclinical (1986)
Press Release (12)
Prostate cancer (25)
Psychedelics (2)
Radiopharmaceuticals (83)
Rare diseases (65)
Real estate (1485)
Recruiting (19)
Regulatory (6175)
Reports (8)
Research institute (640)
Resumes & cover letters (63)
RSV (11)
Schizophrenia (15)
Series A (24)
Series B (16)
Service/supplier (1)
Sickle cell disease (11)
Southern California (544)
Spinal muscular atrophy (28)
Sponsored (6)
Startups (759)
Stomach cancer (4)
Supply chain (11)
The Weekly (3)
United States (5056)
Vaccines (135)
Venture capitalists (5)
Webinars (6)
Weight loss (26)
Women's health (5)
Worklife (5)
Date
Today (57)
Last 7 days (200)
Last 30 days (739)
Last 365 days (8760)
2025 (1953)
2024 (9407)
2023 (11387)
2022 (15118)
2021 (16418)
2020 (15715)
2019 (13587)
2018 (10408)
2017 (10561)
2016 (9575)
2015 (11826)
2014 (8369)
2013 (6482)
2012 (7122)
2011 (7616)
2010 (6677)
Location
Africa (249)
Alabama (6)
Arizona (31)
Arkansas (1)
Asia (14316)
Australia (2603)
California (1263)
Canada (505)
China (191)
Colorado (62)
Connecticut (38)
Delaware (38)
Europe (31132)
Florida (220)
Georgia (46)
Idaho (23)
Illinois (117)
India (6)
Indiana (85)
Iowa (1)
Japan (78)
Kansas (22)
Kentucky (5)
Louisiana (4)
Maine (37)
Maryland (173)
Massachusetts (880)
Michigan (70)
Minnesota (94)
Missouri (16)
Montana (12)
Nebraska (6)
Nevada (18)
New Hampshire (24)
New Jersey (494)
New Mexico (5)
New York (359)
North Carolina (268)
North Dakota (1)
Northern California (532)
Ohio (48)
Oklahoma (3)
Oregon (4)
Pennsylvania (312)
Puerto Rico (4)
Rhode Island (5)
South America (434)
South Carolina (5)
Southern California (544)
Tennessee (17)
Texas (154)
Utah (46)
Virginia (17)
Washington D.C. (10)
Washington State (133)
West Virginia (1)
Wisconsin (14)
192,927 Results for "huyabio international".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
HUYABIO Presents Positive Phase 2 Data on HBI-8000 and Nivolumab Combination for Advanced Melanoma
November 8, 2024
·
4 min read
Press Releases
HUYABIO Validates Protective Mechanism for Antiarrhythmic Drug HBI-3000 in AF Patients, Paving the Way for a New Era in Atrial Fibrillation Treatment
November 15, 2024
·
3 min read
Drug Development
HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL
HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF).
June 14, 2022
·
2 min read
HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF PHASE 2 ATRIAL FIBRILLATION TRIAL
First patient dosed in trial investigating cardioversion of recent-onset atrial fibrillation [02-November-2021] SAN DIEGO , Nov. 2, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that the first patient has been dosed in a Phase 2 study of HUYABIO’s novel drug
November 2, 2021
·
3 min read
Biotech Beach
HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan
HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the product launch in Japan for Hiyasta® tablets to treat relapsed and/or refractory (R/R) adult T-cell leukemia/lymphoma (ATLL).
October 19, 2021
·
2 min read
Policy
HUYABIO International Receives Regulatory Approval For Hiyasta® Monotherapy Of Peripheral T-Cell Lymphoma In Japan
HUYABIO International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval of HBI-8000, brand name Hiyasta®, monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.
November 30, 2021
·
2 min read
Policy
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
Shenzhen Chipscreen Biosciences’ licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry of Health, Labour and Welfare in Japan.
December 1, 2021
·
3 min read
Business
Huyabio International Announces Global Clinical Trial Collaboration With Bristol Myers Squibb In Melanoma
HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced that it had entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY) to evaluate the combination of HUYABIO’s HBI-8000, an epigenetic immunomodifier, and Opdivo® (nivolumab), a PD-1 blocking antibody
March 30, 2021
·
2 min read
Policy
HUYABIO International Receives Regulatory Approval for HBI-8000 Monotherapy of Adult T-cell Leukemia/Lymphoma in Japan
HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, today announced the regulatory approval for HBI-8000 monotherapy of relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL) by the Japanese Pharmaceuticals and Medical Devices Agency.
June 23, 2021
·
2 min read
Biotech Beach
HUYABIO Announces HBI-8000 Brand Name of Hiyasta™
HUYABIO International announced today that HBI-8000 will be marketed under the brand name Hiyasta ™ in Japan .
June 24, 2021
·
2 min read
1 of 19,293
Next
